130 related articles for article (PubMed ID: 12749725)
21. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
Cecchin E; De Mattia E; Ecca F; Toffoli G
Drug Resist Updat; 2018 Jul; 39():18-40. PubMed ID: 30075835
[TBL] [Abstract][Full Text] [Related]
22. DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens.
Leon LG; Giovannetti E; Smid K; van Houte BP; Hanauske AR; Giaccone G; Peters GJ
Curr Drug Metab; 2011 Dec; 12(10):956-65. PubMed ID: 21787269
[TBL] [Abstract][Full Text] [Related]
23. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.
Shirota Y; Stoehlmacher J; Brabender J; Xiong YP; Uetake H; Danenberg KD; Groshen S; Tsao-Wei DD; Danenberg PV; Lenz HJ
J Clin Oncol; 2001 Dec; 19(23):4298-304. PubMed ID: 11731512
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients.
Gnoni A; Russo A; Silvestris N; Maiello E; Vacca A; Marech I; Numico G; Paradiso A; Lorusso V; Azzariti A
Curr Drug Metab; 2011 Dec; 12(10):918-31. PubMed ID: 21787270
[TBL] [Abstract][Full Text] [Related]
25. Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients.
Zhang L; Zhao J; Yu B; Song X; Sun G; Han L; Wang L; Dong S
Cancer Genet; 2017 Dec; 218-219():51-57. PubMed ID: 29153096
[TBL] [Abstract][Full Text] [Related]
26. ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt.
Kassem AB; Salem SE; Abdelrahim ME; Said AS; Salahuddin A; Hussein MM; Bahnassy AA
Exp Mol Pathol; 2017 Feb; 102(1):78-85. PubMed ID: 28088319
[TBL] [Abstract][Full Text] [Related]
27. Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer.
Cubillo A; Rodriguez-Pascual J; López-Ríos F; Plaza C; García E; Álvarez R; de Vicente E; Quijano Y; Hernando O; Rubio C; Perea S; Sanchez G; Hidalgo M
Am J Clin Oncol; 2016 Jun; 39(3):236-42. PubMed ID: 24517959
[TBL] [Abstract][Full Text] [Related]
28. Pharmacogenetics in chemotherapy of colorectal cancer.
Henriette Tanja L; Guchelaar HJ; Gelderblom H
Best Pract Res Clin Gastroenterol; 2009; 23(2):257-73. PubMed ID: 19414151
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.
Cortejoso L; López-Fernández LA
Pharmacogenomics; 2012 Jul; 13(10):1173-91. PubMed ID: 22909207
[TBL] [Abstract][Full Text] [Related]
30. Pharmacogenetics and irinotecan therapy.
Hahn KK; Wolff JJ; Kolesar JM
Am J Health Syst Pharm; 2006 Nov; 63(22):2211-7. PubMed ID: 17090741
[TBL] [Abstract][Full Text] [Related]
31. Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan.
Martinez-Balibrea E; Manzano JL; Martinez-Cardus A; Moran T; Cirauqui B; Catot S; Taron M; Abad A
Oncol Rep; 2007 Mar; 17(3):637-45. PubMed ID: 17273745
[TBL] [Abstract][Full Text] [Related]
32. Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.
Salgado J; Zabalegui N; Gil C; Monreal I; Rodríguez J; García-Foncillas J
Oncol Rep; 2007 Feb; 17(2):325-8. PubMed ID: 17203168
[TBL] [Abstract][Full Text] [Related]
33. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
Massacesi C; Terrazzino S; Marcucci F; Rocchi MB; Lippe P; Bisonni R; Lombardo M; Pilone A; Mattioli R; Leon A
Cancer; 2006 Mar; 106(5):1007-16. PubMed ID: 16456808
[TBL] [Abstract][Full Text] [Related]
34. Molecular genetic alterations as potential prognostic indicators in colorectal carcinoma.
Hamilton SR
Cancer; 1992 Mar; 69(6 Suppl):1589-91. PubMed ID: 1540900
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenetics in colorectal cancer: a systematic review.
Funke S; Brenner H; Chang-Claude J
Pharmacogenomics; 2008 Aug; 9(8):1079-99. PubMed ID: 18681783
[TBL] [Abstract][Full Text] [Related]
36. Molecular biology of colorectal cancer.
Gryfe R; Swallow C; Bapat B; Redston M; Gallinger S; Couture J
Curr Probl Cancer; 1997; 21(5):233-300. PubMed ID: 9438104
[TBL] [Abstract][Full Text] [Related]
37. Individualizing chemotherapeutic treatment of colorectal cancer.
Crews KR
Am J Health Syst Pharm; 2006 May; 63(9 Suppl 2):S12-7. PubMed ID: 16641252
[TBL] [Abstract][Full Text] [Related]
38. [Role of pharmacogenetics in chemotherapy of colorectal cancers].
Ceppa F; Fontan E; Cremades S; Bihannic R; Bousquet A; Beauvillain L; Burnat P
Rev Med Interne; 2007 Sep; 28(9):594-602. PubMed ID: 17624636
[TBL] [Abstract][Full Text] [Related]
39. Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002).
Tsuburaya A; Sugimoto N; Imamura H; Nishikawa K; Imamoto H; Tsujinaka T; Esaki T; Horita Y; Kimura Y; Fujiya T; Takayama O; Oono R; Yabusaki H; Taguri M; Morita S; Yamada Y; Tan P; Ninomiya M; Furukawa H; Sasako M
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):e45-51. PubMed ID: 27142170
[TBL] [Abstract][Full Text] [Related]
40. Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up.
Lassmann S; Hennig M; Rosenberg R; Nährig J; Schreglmann J; Krause F; Poignee-Heger M; Nekarda H; Höfler H; Werner M
Int J Colorectal Dis; 2006 Apr; 21(3):238-47. PubMed ID: 16132996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]